Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial of ANS-03 in patients with locally advanced or metastatic tumors harboring a ROS1 or NTRK alteration

Next Previous
X
Search
Trial Profile

A clinical trial of ANS-03 in patients with locally advanced or metastatic tumors harboring a ROS1 or NTRK alteration

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 11 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ANS-03 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Dec 2024 New trial record
    • 04 Dec 2024 According to an Avistone Biotechnology media release, the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for ANS03. Enrollment of patients with locally advanced or metastatic tumors harboring a ROS1 or NTRK alteration is expected to begin in Q1 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top